Kinnate Biopharma Future Growth
Future criteria checks 0/6
Kinnate Biopharma is forecast to grow earnings and revenue by 13.8% and 72.3% per annum respectively while EPS is expected to grow by 32.6% per annum.
Key information
13.8%
Earnings growth rate
32.6%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 72.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 03 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -69 | -40 | N/A | 2 |
| 12/31/2025 | N/A | -56 | -36 | N/A | 2 |
| 12/31/2024 | N/A | -57 | -35 | N/A | 3 |
| 12/31/2023 | N/A | -113 | -100 | -100 | N/A |
| 9/30/2023 | N/A | -127 | -107 | -106 | N/A |
| 6/30/2023 | N/A | -127 | -102 | -102 | N/A |
| 3/31/2023 | N/A | -122 | -96 | -96 | N/A |
| 12/31/2022 | N/A | -116 | -92 | -89 | N/A |
| 9/30/2022 | N/A | -111 | -91 | -88 | N/A |
| 6/30/2022 | N/A | -105 | -88 | -85 | N/A |
| 3/31/2022 | N/A | -99 | -81 | -79 | N/A |
| 12/31/2021 | N/A | -90 | -72 | -71 | N/A |
| 9/30/2021 | N/A | -77 | -62 | -62 | N/A |
| 6/30/2021 | N/A | -63 | -53 | -53 | N/A |
| 3/31/2021 | N/A | -49 | -41 | -41 | N/A |
| 12/31/2020 | N/A | -36 | -30 | -30 | N/A |
| 9/30/2020 | N/A | -26 | -20 | -20 | N/A |
| 12/31/2019 | N/A | -10 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6KB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6KB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6KB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6KB is forecast to have no revenue next year.
High Growth Revenue: 6KB is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6KB's Return on Equity is forecast to be high in 3 years time